Zimmermann, P and Perrett, KP and Ritz, N and Flanagan, KL and Robins-Browne, R and van der Klis, FRM and Curtis, N and Abruzzo, V and Allen, K and Bonnici, R and Casalaz, D and Elborough, H and Freyne, B and Gardiner, K and Germano, S and Kollmann, T and Messina, N and Morrison, C and Nakaya, H and Ponsonby, AL and Shann, F and South, M and Vuillermin, P and the MIS BAIR group, Biological sex influences antibody responses to routine vaccinations in the first year of life, Acta Paediatrica, International Journal of Paediatrics, 109, (1) pp. 147-157. ISSN 0803-5253 (2020) [Refereed Article]
Aim: We investigated the effect of early-life factors, namely sex, delivery mode, feeding method and antibiotic exposure, on antibody responses to routine vaccinations administered during the first year of life.
Methods: One and seven months after the primary course of routine vaccines and 1 month after routine vaccines at 12 months of age, antibodies against 26 vaccine antigens were measured in 398 healthy infants. The geometric mean concentration (GMC) of antibodies (adjusted for effect modifiers with multiple linear regression) and the seroprotection rate for each vaccine were compared for each early-life factor.
Results: Sex had an influence on GMCs. Antibody concentrations were significantly lower at 7 months of age in females for tetanus and filamentous haemagglutinin and at 13 months of age for pertactin. In contrast, at 13 months of age, antibody concentrations were significantly higher in females for polio type 3, pneumococcal serotype 6A and measles. Sex did not have an influence on seroprotection rates. Delivery mode, feeding method and antibiotic exposure did not exert a substantial influence on vaccine antibody concentrations.
Conclusion: There is a difference between males and females in the humoral response to routine vaccinations in the first year of life.
|Item Type:||Refereed Article|
|Research Division:||Biomedical and Clinical Sciences|
|Research Field:||Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)|
|Objective Group:||Clinical health|
|Objective Field:||Prevention of human diseases and conditions|
|UTAS Author:||Flanagan, KL (Dr Katie Flanagan)|
|Web of Science® Times Cited:||5|
Repository Staff Only: item control page